George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of AGM

15 Nov 2018 07:00

RNS Number : 4154H
Akers Biosciences, Inc.
15 November 2018
 

November 15, 2018

Akers Biosciences, Inc.

Notice of Annual Meeting of Shareholders

 

Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, announces that the Company has filed a Schedule 14A with the U.S. Securities and Exchange Commission giving notice of the annual meeting of shareholders ("Schedule 14A"). The Schedule 14A will shortly be sent to all shareholders and holders of depository interests and is available to view on Akers Bio's website at www.akersbio.com or on www.sec.gov.

 

The Annual Meeting of Shareholders will be held at 11.00 a.m. EST on December 7, 2018, at the offices of Ellenoff Grossman & Schole LLP, 1345 6th Ave. New York, NY 10105, United States.

 

Inquiries:

 

Akers Biosciences, Inc.

Howard R. Yeaton, Chief Executive Officer and Interim Chief Financial Officer

Tel. +1 856 848 8698

 

finnCap (UK Nominated Adviser and Broker)

Ed Frisby / Scott Mathieson (Corporate Finance)

Tel. +44 (0)20 7220 0500

 

Vigo Communications (Global Public Relations)

Ben Simons / Fiona Henson

Tel. +44 (0)20 7390 0234

Email: akers@vigocomms.com

 

About Akers Biosciences, Inc.

 

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

 

Additional information on the Company and its products can be found at www.akersbio.com.

 

Cautionary Note Regarding Forward-Looking Statements

 

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, compliance with the requirements of various regulatory agencies and certain NASDAQ Stock Market listing rules, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions, as they relate to the Company, its subsidiaries, or its management. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, performance, prospects, and opportunities to may differ materially from those set forth in, or implied by, the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NOABABBTMBTBMLP
Date   Source Headline
6th Mar 20197:00 amRNSResult of Special Meeting of Shareholders
6th Feb 20199:00 amRNSHolding in Company
6th Feb 20197:01 amRNSForm DEFA14A Filing - Additional Proxy Materials
6th Feb 20197:00 amRNSNotice of Special Meeting of Shareholders
5th Feb 20191:00 pmRNSFurther Re. Directorate Change
28th Jan 20197:00 amRNSForm PRE 14A Filing
28th Dec 20183:45 pmRNSDirector/PDMR Shareholding
19th Dec 20184:45 pmRNSIntention to Delist from AIM
18th Dec 20186:00 pmRNSIssue of Equity
10th Dec 20187:00 amRNSResult of AGM & Form 8-K Filing
26th Nov 20182:00 pmRNSFurther Re. Notice of AGM
19th Nov 20182:00 pmRNSFurther Re. Strategic Update
16th Nov 20184:00 pmRNSReverse Stock Split Update
15th Nov 20187:00 amRNSNotice of AGM
15th Nov 20187:00 amRNS3rd Quarter 2018 Results
12th Nov 20187:00 amRNSForm 8-K Filing
8th Nov 20187:30 amRNSSuspension - Akers Biosciences, Inc.
8th Nov 20187:00 amRNSTemporary Suspension of Share Trading on LSE
7th Nov 20182:50 pmRNSStrategic Update & Reverse Stock Split
2nd Nov 20184:15 pmRNSIssue of Equity - Completion & Form 8-K/A Filing
2nd Nov 201810:52 amRNSUpdate Re Issue of Equity
31st Oct 20181:35 pmRNSIssue of Equity & Form 8-K
19th Oct 20182:53 pmRNSForm 8-K Filing
19th Oct 20187:00 amRNSDirectorate Change
12th Oct 20187:00 amRNSForm 8-K/A Filing & Other Updates
8th Oct 20187:00 amRNSDirectorate Change & Other Information
13th Sep 20187:00 amRNSDirectorate Change - Form 8-K Filing
15th Aug 20187:00 amRNS2nd Quarter & H1 2018 Results
27th Jul 20183:00 pmRNSHolding(s) in Company
26th Jul 20187:30 amRNSRestoration - Akers Biosciences Inc.
26th Jul 20187:00 amRNSMailing of 2017 Annual Report
20th Jul 20183:05 pmRNSIssue of Equity
20th Jul 20183:00 pmRNSCorrection: Issue of Equity
18th Jul 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
16th Jul 20187:03 amRNS1st Quarter 2018 Results
16th Jul 20187:02 amRNSFinal Results 2017 (Restated)
16th Jul 20187:01 amRNS3rd Quarter 2017 Results (Restated)
16th Jul 20187:00 amRNS2nd Quarter 2017 Results (Restated)
3rd Jul 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
2nd Jul 20187:30 amRNSSuspension - Akers Bioscience, Inc
29th Jun 20187:00 amRNSTemporary Suspension
21st Jun 20187:00 amRNSNotification of Class Action
20th Jun 20187:22 amRNSForm 8-K Filing
18th Jun 20187:00 amRNSForm 8-K Filing
6th Jun 20187:00 amRNSForm 8-K/A Filing
4th Jun 20187:00 amRNSForm 8-K Filing
31st May 20187:25 amRNSUpdate Re. Nasdaq Minimum Bid Price Requirement
29th May 20187:00 amRNSDirectorate Change
29th May 20187:00 amRNSWithdrawal of 510(k) Submission - Chlamydia Assay
29th May 20187:00 amRNSNotice of Form 10-Q Filing Delinquency from Nasdaq

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.